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ABSTRACT

y-Aminobutyric acid inhibits interleukin-ip stimulated release of interleukin-6
from rat C6 glioma cells in vitro: Evidence for role of p38 MAP Kinase
by
Raghuram Royyuru
Dr. Bryan L. Spangelo, Examination Committee Chair
Professor
University o f Nevada, Las Vegas
The central nervous system (CNS) is composed o f two cell types neurons and glial
cells. Neurons mediate the function of sending and receiving signals in the brain. Glial
cells provide nutrients and strength to the CNS. Glial cells are composed of microglia,
oligodendroglia, and astrocytes. Activated microglia is the main source for the cytokine
interleukin-1 (IL-1). Activated cytokines are elevated in Alzheimer’s disease (AD)
(Tuppo, 2005), a neurodegenerative disorder. Cytokines mediate the inflammatory
response, which is required for cells to carry out part o f its normal functions. When
inflammation is chronic it damages the cells and leads to the adverse effects like neuronal
death which is a primary symptom for AD.
IL -lp stimulates IL-6 through by activation of a series o f complexes, involving
mitogen activated protein kinases (MAPK) and transcription factors. Increased lL-6 leads
to neurodegeneration and finally leads to the death o f the patient. IE -1P is activated by
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cell stimuli like stress, oxidative damage and plaques, amyloid deposition and tumor
activating proteins.
We investigated the pathway o f IL -ip stimulated IL-6 release and the involvement of
different M APK’s effectors. We used three different MAPK inhibitors SB203580 for
p38, SP600125 for JNK, and PD98059 for ERK kinases. We described the role of yAminobutyrie acid (GABA) and G A B A b receptor in the inhibition o f IL-1 P signal
transduction.
Bioassay results suggest that SB203580 inhibited IL-6 release while the other two
MAPK inhibitors had no effect. It also suggested GABA inhibits the IL -ip stimulated
release o f lL-6. By Western analysis we found that IL -lp activated p38 MAPK time
dependent fashion and we saw a maximum stimulation occurred at 15 min.
To elucidate the IL -lp signal transduction more clearly we investigated the role of
the G ABA receptor subclass. We investigated the role o f G ABA subclass receptors in ILip stimulation o f lL-6 from C6 cells. We used muscimol (agonist for G A B A a) and
Baclofen (agonist for G A B A b). Our result suggested that G A B A b receptor is involved in
IL -ip stimulation o f IL-6 release in C6 cells, while the G A B A a receptor agonist
muscimol had no effect.
We investigated the role o f SRIF in the activation of p38 MAPK by IL -ip and found
that it enhanced the activation o f p38. From the above results we described the IL-lp
stimulated IL-6 release and the involvement o f p38. GAB A attenuates the stimulated
release of IL-6 and suppressed p38 activation. Thus, GABA and its mimetics may he
clinically effective as a treatment for AD.
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CHAPTER 1

INTRODUCTION
Central Nervous System
The central nervous system (CNS) is made o f two cell types namely neurons and glial
cells. Neurons send and receive electro chemical signals and glia provide nutrition and
support to neurons. Neurons are composed o f a cell body, dendrites and axons. Dendrites
receive signals and send signal to axon. Axonal terminations pass the signal to other
neurons. Except for neurons from the hippocampus most neurons cannot grow after
damage. In addition to supporting neurons, glia digest the parts o f dead neurons. Glial
cells include microglia, oligodendroglia and astrocytes. Microglia are the smallest o f glial
cells. Their main function is to protect brain from microorganisms. Oligodendrocytes
function is to provide support to neurons and produce of myelin which insulates the
axons o f neurons. Astrocytes function is to provide support to neurons by providing
nutrients and breakdown glucose to lactose and release lactate into the extracellular fluid
surrounding neurons. Astrocytes also perform an action called phagocytosis hy which
they remove neuronal debris. Activated microglia is observed in neurodegenerative
diseases such as Alzheimer’s disease (AD). AD is observed in 4.5 million people in
United States. Elevated levels o f cytokines are observed in AD (Tuppo, 2005). Cytokines
are low molecular weight proteins which mediate and regulate immune response,
inflammation, and apoptosis (Streit, 2004). Cytokines are produced by many cells but
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predominantly by T cells and macrophages. Cytokines act at very low concentrations for
a very short period o f time.
Different types o f cytokines include lymphokine cytokines which are made by
lymphocytes, monokine cytokines which are made by mononeytes, chemokine cytokines
which control chemotactic activity and interleukin cytokines which act in a paracrine
fashion in the immune system. Cytokines act via binding to their receptor and thereby
subsequently stimulates the release o f a second messenger that leads to a cellular
response. Cytokines aetivate other cytokines and they may also aet synergistically with
other cytokines.

Interleukins and Their Signaling Pathways
Interleukins play a major role in cell differentiation and proliferation. Interleukins
consists of interleukin-1 (IL-1) through interleukin (lL-12) (Carol, 1997). Other groups of
cytokines such as interferon inhibit viral replication. Chemokines attract lymphocytes to
the site of cellular damage. Interleukin-1 is the most important immune response
modifying interleukin. IL-1 also induces expression o f Interferon-y (INF-y). The IL -ls (a,
andP) are secreted primarily by macrophages but also from neutrophils, endothelial cells,
smooth muscle cells, glial cells, astrocytes, B and T-cells, fibroblasts and keratinoeytes .
These cells express IL-1 upon cellular stimulation. Tumor necrosis factor-a (TNF-a) also
acts like IL -ip (Carol, 1997). There are two distinct IL-1 (structure shown in figure 1)
proteins IL -la (17kDa) and IL -ip (17kDa) (Warren, 1990). Both forms are synthesized
from a precursor o f approximately 35 kDa. The mature proteins are produced by
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proteolytic cleavage which is done hy the enzyme interleukin-Ip converting enzyme
(ICE).
IL-1 binds to IL-1 receptor and this leads to the activation o f interleukin receptor
associated kinase -1 and 2 (IRAK-1 and lRAK-2) (Spangelo, 2004). This activates the
recruitment o f TRAP6 (TNF receptor associated factor 6). TRAF6 activates two
pathways one leading to the activation o f NF-kB and other to the activation of c-Jun
pathway. TRAF and evolutionarily conserved signaling intermediate (ECSIT) in toll
pathway leads to activation of c-Jun pathway by activating mitogen activated protein
kinase (MAPK). TRAF associated with TAKl binding protein/TGFp activated kinase
(T A B l/T A K l) leads to the activation o f NF-kB pathway. Either o f the pathways finally
leads to the activation o f transcription factors and alterations in the gene expression.
INF-a/p (induced by IL-1) binds to its receptor INF receptor-1 and activates the
JAK/STAT pathway or Tyk2/STAT pathway. Phosphorylated STATl and STAT2 and
activate p48. INF-y also activates GAGA (GAF) factor a transcription factor by
JAK7STAT pathway but do not activate p48 (Biron, 1998).
TNF activates TRAF2 which in turn activates the MAPK cascade finally activating
NF-kB and thus produces a cell response. TNF-a and TNF-P (17 kDa, and 25 kDa
respectively bind to common receptors (Vilcek, 1991). TNF-a and IL-1 share many proinflammatory properties. TNF-P shares properties o f TNF-a by inducing apoptosis in
tumor cells and virally infected cells.
lL-6 (structure in Figure 2) is a B-cell differentiating and T-cell activating cytokine
and produced by macrophages fibroblasts, endothelial cells and activated T-helper cells
(Akira, 1993). It is a 185 amino acid protein glycosylated at 73 and 172 positions. It is
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synthesized as a precursor protein which is 212 amino acids. Amino acid sequence of
precursor and mature IL-6 is given in the figureS. IL -ip and TNF-a stimulates IL-6
(Haddad, 2002). IL-6 enhances glucocorticoid expression. In addition to inflammation
and hematopoiesis, IL-6 also induces neuronal differentiation and bone loss.
IL-6 signals through a receptor consisting o f an a subunit (which is ligand specific)
and gpl30 subunit (which shared in common with other cytokines) (Hirano, 1992). These
subunits lead to activation o f JAK kinase and ras mediated signaling. JAK kinase
activates STAT transcription factors. (Bode, 2003). The ras mediated pathway acts
through Src homolog 2 containing domain (she). Growth factor receptor-bound protein 2
(Grb-2) and Son o f sevenless homolog l(S os-l) upstream and MAP kinase downstream.
Finally, activation of transcription factors such as AP-1 and Serum response element
(SRE) leads to gene transcription (Bode, 2003, Heinrich, 1998).

Mitogen Activated Protein Kinase
MAPK pathways transduce a large variety o f external signals which lead to internal
responses like cell differentiation, inflammation and apoptosis. The MAPK family yields
signal in the form o f phosphorylation. MAPK kinase kinase which activates MAP kinase
kinase activates MAP kinase leading to a biological response. There are three major
groups o f MAPK which include p38 MAPK family, extracellular regulating kinase
family (ERK) and c-Jun NHz terminal kinase family (JNK) (Tanoue, 2002). The p38
family includes four isoforms (p38a, p38p, p38y, and p38ô) (Dong, 2002), while the ERK
family consists o f two isoforms, ER K l and ERK2. JNK consists of three isoforms which
include JN K l, JNK2, and JNK3 (Chang, 2001).
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Each MAPK family has unique activators, substrates and inactivators. p38 members
are activated by stress stimuli and by different cytokines. p38 kinase is required for
regulation o f apoptosis, cell cycle arrest, cytokine production and inflammation. ERK
kinases are activated by cytokines and growth factors and regulate mitogenic and antiapoptotic signals. JNK family is activated by stress stimuli and growth factors and
regulates cell cycle arrest and progression and cytokine production.
For a MAP kinase to be activated it should be phosphorylated at two positions which
includes Thr and Tyr residues. Such dual phosphorylation groups are located in the
activation loops o f a MAP kinase family. For p38 it is Thr-Gly-Tyr motif, for ERK it is
Thr-Glu-Tyr m otif and for JUN it is Thr-Pro-Tyr motif. MEK activates MAP kinases by
phophorylating Ser, Thr and Tyr residues (Platanias, 2003). MKK3, MKK4, and MKK6
activate p38. MKKl and MKK2 aetivate ERK, and MKK4 and MKK7 activates JNK
family of kinases (Dong, 2002). MKK6 activate all the 3 isoforms o f p38 while MKK3
activates only p38a and p38y. Activation o f MAPKKK or MAPKK occurs downstream
o f G-protein activation which is regulated by Guanine Exchange Factor (GEF) (Platanias,
2003). Phosphorylation o f MAPK is important for may biological responses such as
phosphorylation o f transcriptional factors, nuclear chromatin remodeling, immediate gene
expression, cytokine production, cell cycle progression and apoptosis. MAPK signaling
cascade in shown in Figure 3.

y-Aminobutyricacid (GABA)
GABA is the primary inhibitory neurotransmitter in the adult CNS and is present in
most of the neurons and produces inhibitory and hyperpolarizing effects on neurons
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(structure shown in figure 4). Hyperpolarizing effects are due to the excessive influx of
chloride ion in to cells. Thus by creating differences in the eleetrochemical gradient it
inhibits the transfer o f messages from one neuron to other. GABA is converted from
glutamic acid by the action glutamic acid decarboxylase (GAD) (Guin, 2003). Following
the release o f GABA it can be taken up by either astrocytes or neurons (Semyanov,
2004). GABA is then degraded with in cells and synaptic cleft by GABA transaminase.
Hypoactivity o f GABA leads to epilepsy, anxiety, stress, and sleep disorders (Guin,
2003) . GABA is composed o f two receptors, GABA a and GABA b. GABA a is an
ionotropic receptor and GABA b is a metabotropic receptor.
GABAergic neurotransmission can be divided into two components; fast and slow.
When GABA bind to GABAa receptor it a fast response and occurs in a time period of
one milli second, where as GABA binding to GABAb receptor is a slow response and
requires one second (Guin, 2003). When GABA binds to GABAa receptor it acts through
ion ligand gated chloride channels. When GABA bind to GABAb receptor it acts through
G-protein coupled receptors and a second messenger leading to opening of near by
potassium channels. GABAa receptor is a heteromeric pentamer. Currently, 20 GABAa
receptor subunits have been identified, including six a, four p, three y, one o f Ô, e, ti, 0
and three p subunits (Lambert, 2003; Steiger, 2004). The a and P subunit play an
important role in GABAA/muscimol affinity (structure o f muscimol is shown in figure 5).
GABA a receptor is most prevalent in mammalian brain. There are three binding sites
on GABA a receptors, including the GABA site, second the benzodiazepine site, and the
barbiturate site. Pharmacologically, muscimol is considered to be an agonist o f GABA a
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receptor. Benzodiazepines increase GABA binding to GABA a receptor and thereby
increase chloride influx.
G A B A b receptor is a heterodimer composed o f G A B A b R1 (G A B A b receptor 1) and

GABA R2 (GABA receptor 2) (Bettler, 2004). The highest concentration of G A BA b
receptor is in interpenduncular nuclei and cerebellum (Bowery NG, 2002). Baclofen
(structure shown in figure 6) is considered an agonist to G A B A b receptor. Occupancy of
this receptor by baclofen results in muscle relaxation.

Somatostatin
Somatostatin (SRIF) has neuromodulatory effects in CNS. Somatostatin inhibits the
IL -ip stimulated release o f IL-6. It is present in hypothalamus, pancreas, GI track, and in
the cerebral cortex. In CNS it acts as neurotransmitters its function include inhibition of
growth hormone, insulin, ACTH and glucagon and as an anti-inflammatory factor. Two
forms SRIF are synthesized one corresponding to SRIF-14 (14 amino acids) and other
SRIF-28 (28 amino acids). Both forms o f SRIF are formed by proteolytic cleavage of
prosomatostatin (10.2 kDa and 92 amino acids), which is produced by preprosomatostatin
(12.7 kDa and 116 amino acids).
SRIF has five different receptors namely SRIF,.5. Each receptor is G-protein coupled
receptors and these interactions with G-proteins leads to several effects in the cell
including inhibition o f adenyl cyclase, and calcium channel activity, stimulation of
potassium channel and tyrosine phosphate activity, and regulation o f intracellular pH.
SRIF acts by both paracrine and autocrine actions. Interestingly, in AD the levels of SRIF
are decreased in cortex o f brain. (Foy, 1994)
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Cytokines and Inflammatory Disease
Inflammation is an immune response which requires coordination between different
cell types including macrophages and lymphocytes. Inflammation is a process of
protective response to a infection or trauma. Inflammation is characterized by increased
blood flow and vascular permeability along with accumulation o f fluids, leukocytes and
cytokines. Inflammation can be protective but when inflammation is chronic cellular
damage can leads to the adverse effects including neuronal death and neurodegeneration.
Cytokines such as IL-1, IL-6 and TNF control the inflammatory response. Elevated levels
of cytokines are observed in neuronal disorders such as AD.
IL-1 and TNF cause fever through alteration of body temperature set by the
hypothalamus (Warren, 1990). IL-2 acts a key moderator for T-cell proliferation and
activation. IL-3 and IL-5 stimulate proliferation (Arai, 1991) and lL-10 and IL-4 activates
B cell responses via T helper cell snb population (Carol, 1997). IL-6 stimulates
differentiation of bone marrow stem cells and secretion o f antibody proteins from plasma
cells. IL-7 stimulates differentiation of stem cells into progenitor B and T cells
(Goodwin, 1998). Finally, IL-8 stimulates chemotaxis (Miller, 1992). Excessive
production of cytokines, especially IL -ip, is seen in the pathology o f AD.
Activated microglia stimulates the production IL-1 (Kim, 2005). AD patients have a
six fold increase in plaque deposition compared to the unaffected patients. Plaque
formation is dependent on expression o f P-amyloid protein. Amyloid precursor protein
(AFP) is a precursor protein for the formation o f P-amyloid protein (Bemhardi, 2004).
IL-1 helps in up regulation o f APP.
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Current evidence suggests that GABA and SRIF down regulate the IL -ip stimulation
o f IL-6 hy inhibiting one or more MAP kinases. CNS patients suffering from AD present
with a degradation o f somatostaticergic receptors while the GABAergic interruption is
unhalted.

Hypothesis Statement
Interleukin-6 (IL-6) is a 212 amino acid cytokine synthesized by various types of
eells. It plays an important role in the immune system and the CNS. Elevated levels of
IL-6 are observed in AD whieh is an progressive brain disorder where gradually brain
cells gets destroyed and leads to a progressive decline in mental function. Previous
studies suggest that IL -ip dose dependently stimulates the release o f IL-6. In this study,
we are investigating the role o f p38 MAPK, GABA, G A BA a, G A B A b, and PD98059 an
ERK inhibitor in C6 glioma cells. Previous studies suggest inhibitor o f p38 MAPK
SB203580 (structure shown in figure 7) inhibits the IL-lp stimulated release o f IL-6
while an JNK inhibitor SP600125 had no effect (Spangelo, 2004). We hypothesize that
p38 MAPK will be stimulated in a dose and time dependent manner with IL-1 p. From
the results we hypothesized that GABA attenuates the IL -ip stimulated p38 MAPK in C6
cells and further G A B A b will be involved in the attenuation mechanism of stimulated IL6 release. We further hypothesize that, PD98059 (structure shown in figure 8) will not be
have any effect in the stimulated release o f IL-6 and thus the role o f ERK (and from
previous studies JNK MAPK) can be discounted. Our results provide a better
understanding the inflammation mechanism underlying AD.
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CHAPTER 2

MATERIALS AND METHODS
Chemicals and reagents
The 7TD1 hybridoma cell line was obtained from Dr. J. Van Sniek, Ludwig Institute
(Brussels, Belgium). The C6 glioma cell line was obtained from the American Tissue
Type Culture Colleetion (Rockville, MD). Recomhinant rat interleukin-1P (IL-ip) was
obtained from PeproTech Inc. (Rocky Hill, NJ). Recombinant murine interleukin-6 (IL6) was obtained from R & D Systems (Minneapolis, MN). GABA (y-amino-n-butyric
acid), recombinant somatostatin-14 (SRIF-14), recombinant somatostatin-28 (SRlF-28),
isopropanol (reagent grade), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tétrazolium
bromide), antibiotic mix, were obtained from Sigma Chemical Co. (St. Louis, MO).
RPMI-1640, fetal bovine serum (FBS), horse serum (HS), and trypsin were obtained
from Gibco (Grand Island, NY). Fetal calf serum (FCI) was obtained from Hyclone
(Logan, UT). Trypan blue were obtained from Fisher Scientifie (Santa Clara, CA).
Primary Antibodies was obtained from Cell Signaling Technology (Beverly, MA).
Secondary Antibodies was obtained from KPL incorporation (Gaithersburg, CT).

C6 glioma cell culture
The C6 glioma cells were maintained in continuous culture in a humidified
atmosphere o f 5% C0z-95% air at 37 °C in RPMI-1640 medium supplemented with 10%

10
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FBS and PSN antibiotic mix. After 3 days in culture the C6 cells were removed from the
tissue culture flask using 4mL o f 0.25% trypsin. Trypsin was deactivated by adding 6mL
of C6 culture media. The C6 cells were centrifuged at 400 rpm for 5 minutes, trypsin
was removed, and the cells were resuspended in the C6 culture medium. The C6 cells
were counted using a hemacytometer and were placed either hack into continuous culture
at 1.0 X 10^ cells per 25 em^ flask, or were plated into a 96-well tissue culture plates at
100 X 10^ cells/well with C6 medium for 7TD1 bioassay.
C6 cells were allowed to adhere to the plates for 24 hours, after which the cells
were rinsed twice with 200 pL serum free RPMI-1640. The C6 cells were then exposed
to vehicle (200pL serum free RPMI-1640/well), with and with out IL -ip and other agents
for 24 hours. When inhibitors were used the cells were pretreated with the appropriate
inhibitor for 1 hour in serum free RPMI-1640 and then exposed to the drugs with and
without IL-1 p. After 24 hours the conditioned media was transferred to a new 96-well
plate, which was then stored at 4 °C until measurements for IL-6 by bioassay.

7TD1 Bioassay for IL-6
The 7TD1 eells were maintained in continuous culture in a humidified
atmosphere o f 5% C02-95% air at 37 °C in 10 mL RPMI-1640 supplemented with 10%
FBS, 5mL o f antibiotic mix and 5 pg/mL rmlL-6. After 3 days in culture the 7TD1 cells
were removed from the tissue culture flask using trituration and approximately 600 x 10^
cells were distributed in a 25 cm^ flask (Greiner) for continuous culture. We used the IL6-dependent 7TD1 hybridoma bioassay to quantify the accumulation of IL-6 in the C6
conditioned media as 7TD1 cell growth depends on the presence o f IL-6. Conditioned
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medium (20 qL) is cultured in 96 well tissue culture plates in duplicate in 180 pL RPMI1640 supplemented with 10% FBS and antibiotics in the presence o f 4,000 7TD1 cells for
72-96 hours. Tétrazolium salt (MTT) was used to determine the growth of the 7TD1
cells. MTT is cleaved in active mitochondria to form a dark blue formazan crystal which
can be correlated with OD and IL-6 release. After 72-96 hours 20 pL of 5 mg/mL MTT
is added to each well for 3 % hours. 150 pL o f medium was removed from each well and
the dark blue crystals were dissolved by the addition o f 150 pL o f 0.04 M
HCL/isopropanol to form a dark colored liquid. The plates are stored overnight in the
dark after which the optical densities were determined by a microelisa instrument using a
test wavelength o f 570 nm and a reference wavelength o f 630 nm (Dynatech MR5000).
For each assay a standard curve of rmIL-6 (0.5 to 64 pg/well) was generated. The data
are formed from treatment groups each o f which consists o f 4 observations per group and
are presented as the mean ± SEM. A foe cahrt is provided in figure 9.

Protein Extraction
C6 glioma cells 2x10^ were plated in a 6-well plate and incubated for 24 h. After 24 h
incubation cells were washed 2 times with sf-RPMl 1640. Cells were treated with or
without IL -ip and incubated for 5-60 min. Cells are pretreated 1 hr with selective
inhibitors and then treated with IL -ip ranging from 5-100 ng/mL. After the required
incubation with drugs, cells were washed twice with cold PBS and 200pL of sample
loading buffer (9mL PBS, ImL o f phosphatase inhibitors and one tablet of protease
inhibitors) was added to each well. Cells were scraped with cell scraper and transferred
into microfuge tube along with the extraction buffer. Protein is extracted on ice using
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sonicator in the pulse mode (10 times for 1.5 sec) according to the manufacturer
instructions. Protein thus extraeted is quantified using Pierce BCA kit (procedure is
shown in figure 10). Standards in triplicates and samples in duplieate were incubated for
2hrs in the incubator and read at 562 nm. Average blank values were subtracted from
individual sample and standards. A standard curve of concentration on X-axis and OD on
Y-axis is plotted. Quantified protein samples are either stored at -70° C or diluted 1:1
with 2x sample loading buffer.

SDS-PAGE and Western blotting analyses
The apparatus for SDS-PAGE and Western blotting was purehased from Amersham
Biosciences. SDS-PAGE (10% gels) were performed at 40mA at 4°C. Resolving gel
occupied 75% o f the chamber and water (100-200 uL) was placed on top if it. Following
polymerization water was removed and the stacking gel was added and combs are placed
on the top o f the gel. Combs were removed following polymerization, samples were
introduced into the wells with a standard biotinylated protein ladder (15 uL) and pre
stained protein ladder (10 uL). Before samples are introduced the whole cassette
including the wells was filled with the IX running buffer which got Tris Hcl, glycine and
SDS. SDS-PAGE is ran at a 40mA current and is terminated when the sample reach 1cm
from the bottom o f gel. Gel is transferred into western transfer apparatus along
Membrane sandwich. In the sandwich first the sponge is placed and top o f it blotting
paper, membrane, gel, blotting paper and sponge are placed in the order. Sandwich is
introduced in the apparatus and the gray side o f the sandwich should face the positive end
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filled with western transfer buffer. Western transfer apparatus was ran at 400mA at 4*^C
for 2 hr s.
The membrane was washed with washing buffer for 5 min and blocked with blocking
buffer for 1 h. After blocking with blocking buffer, membrane was washed for 15 min by
changing washing buffer every 5 min. After a 24 h incubation with phosphorylated p38
primary rabbit antibody (obtained from cell signaling #921 IS) which recognizes the
phosphorylated sites Thrl80 and Tyr 182 amino acids o f p38 (1:1000 dilution with
primary antibody dilution buffer) membrane was washed for 15 min and incubated for an
hour with a anti- mouse seeondary antibody (obtained from KPL Inc. #074-1516, 1:5000
dilution with primary antibody dilution buffer) and anti-biotinylated antibody ( 1:1000
with primary dilution buffer). Anti-biotinylated antibody was used for detection of
standard molecular weight ladder. After 2-3 h incubation with secondary antibody and
anti-biotin antibody, membrane was washed for 15 min and treated with ECL Plus
(Amersham) and scanned using Amersham typhoon scanner. ECL Plus is placed on
membrane 5 min before seanning on typhoon. ECL Plus purehased from Amersham is
used to get Fluorescence signal.

Enzyme Linked Immunosorbent Assay (ELISA)
The ELISA kit was purchased from R& D systems. We want to confirm the release
results between ELISA and Bio assay and want to use the best method for the further
experiments. Kit consists of a 96 well rat lL-6 mieroplate, rat IL-6 conjugate, standard,
control, assay diluent, control diluent, wash buffer, color reagent A and B, stop solution,
and plate covers.
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Reagents were prepared according to the manufacturer’s protocol and bought to room
temperature before use. To the center o f each well 50 pL o f assay diluent 50 pL of
standard, control, and sample were added. Plate was covered and gently tapped for 1 min
to mix the wells and incubated for 2 h at room temperature.
Wells were washed with 400 pL of wash buffer for four times. Liquid was
completely removed from the wells and plate was inverted against clean paper towels.
To the plate 100 pL o f IL-6 conjugate was added to each well and covered with
adhesive tape and incubated for 2 h at room temperature. Washing step was repeated for
5 times and a lOOpL o f substrate solution was added and incubated for 30 min protecting
the plate from light.
Finally 100 pL o f stop solution was added to each well and the plate read at 570 nm
within 30 min of adding stop solution.
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CHAPTER 3

RESULTS
7TD1 Bioassay Standard curve
The standard curve is shown in the (Figure 11, 12). A best-fit line equation was
obtained from the graph plotted between rmIL-6 and optical density. Algorithm or linear
regression was and used for the calculation o f IL-6 (pg/well) in the samples. Samples
were diluted so that results will fall within the standard values. Sometime we get a good
linear curve and sometime a good logarithmic curve. Every time we construct both the
curves and depending on the good standard curve we get, we utilize a logarithmic curve
or a linear curve. Theoretically, we should get a good logarithmic curve

C6 glioma Cell Density Effect on Rat Interleukin-ip release of IL-6
Cell density experiment was conducted to determine optimal cell number o f C6
cells/well. We treated our cells with IL -ip (50 ng/mL) and incubated for 24 h and
measured IL-6 using 7TD1 bioassay ( FigurelS). We observed that 100,000 cells/well
gave a maximum stimulation o f IL-6 and used this number for carrying out our future
experiments.

Rat Interleukin-Ip Time Course
IL -lp time course was measured using the 7TD1 bioassay. C6 cells are incubated
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with IL-ip (50 ng/mL) for a time period of 3-48 h (Figure 14). 7TD1 bioassay was
conducted on the samples. At 24 h we observed a maximum stimulation of IL-6 so we
used a 24 h o f incubation in our future experiment.

Rat Interleukin-ip dose response
7TD1 assay was conducted to see the IL -ip stimulated release o f IL-6 . We observed
that as the concentration o f IL -ip increases (5-200ng/mL) there is an increase in the
release of IL-6 (Figurel5). Sometimes we see biphasic stimulation for IL-6. By observing
the curve we use an EC50 o f 50 ng/mL o f IL -lp for our further experiments when using
inhibitors.

ELISA Standard curve on Rat Interleukin-ip stimulated release o f IL-6
ELISA standard curve was obtained using standard concentrations o f IL-6 provided
by the manufacturer (Figure 16).

ELISA Dose Response on Rat Interleukin-ip stimulated release o f IL-6
ELISA was conducted at different concentrations of IL-ip. From the graph (Figure
17) we saw that ELISA was not as sensitive as 7TD1 bioassay. So we performed 7TD1
bioassay for our future experiment.

Effect o f SB203580 on IL-6 release
SB 203580 is a specific inhibitor o f p38 MAPK. We wanted to investigate the
involvement of p38 MAPK in the stimulated lL-6 release. We pre-incubated the C6 cells
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for 1 h both with and without SB203580 (a specific inhibitor o f p38) and incubated along
with and without IL -ip for 24 h. SB203580 (10 pM) inhibited o f the IL-6 release (Figure
18). This suggested p38 MAPK was involved in the IL -ip stimulated mechanism.

Effect o f PD98059 on IL-6 release
PD98059 is inhibitor o f ERK MAPK. We want to investigate the involvement of
ERK MAPK in the stimulated IL-6 release. We pre-incubated the C6 cells for Ihr with
and without PD98059 and incubated along with IL -ip for 24hrs. PD98059 (10 pM) had
no effect on lL-6 release (Figure 18). This suggested ERK MAPK was not be involved in
the IL -ip mechanism.

Effect o f G ABA on IL-6 release
G ABA is an inhibitory neurotransmitter. Decrease in the GABAergic neurons is seen
in the patients with AD. We wanted to investigate the inhibitory effect o f G ABA on IL-6
release. A 500 pM concentration o f GAB A was used in the experiment. C6 cells were
pre-treated with and without G ABA for one hour followed by 24 h incubation with IL-ip.
GABA inhibited IL-6 release (Figure 19).

Role o f GABA subclass receptors in the inhibitory mechanism of GABA
As our results suggest that GABA inhibits the IL-6 we want to see which GABA
subclass receptor is involved. GABA is composed o f the two subclasses GABA a and
GABA b. GABA a acts through ion mediated channel while GABAg acts through the
metabotropic channels.
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We used muscimol (10-50 pM) GABA a receptor agonist which have a Kd of 16-20
nM ( Eberta, 1999), its structure is provided in Figure 9 and baclofen (25-100 pM) a
GABA b receptor agonist which have a Kd o f around 60nM (Ohmori, 1999), its stmcture
is provided in Figure 10.We pre-treated our cells with and with out muscimol and
baclofen followed by incubation o f 24hrs with IL -ip. Our results suggested that baclofen
play a role in the mechanism while the muscimol has no effect (Figure 20, 21).
This suggested that GABAg receptor is involved in the GABA inhibition of p38
MAPK and IL-6.

Effect o f IL -ip Time course on p38 MAPK
p38 MAPK is one o f the three MAPK. As SB203580 inhibited the IL-6 release we
wanted to investigate the activation o f p38 by IL -ip. We treated our cells with IL-ip (25
ng/mL) and incubated for 5-60 min and extracted protein from the cells for western
blotting analysis. Our results suggested that activation o f p38 is maximum at 15min
(Figure 22) and we observed a biphasic stimulation o f p38. Densitometry was performed
on the stimulated bands for graphical representation.

Effect o f IL -ip Dose Response on p38 MAPK
We investigated the dose o f IE -ip which gives maximum stimulation o f p38 MAPK.
We treated our cells with IL -ip (5-100 ng/mL) and incubated for 15 min. Protein was
extracted from incubated cells and analyzed using Western blotting. We observed 25
ng/mL o f IL -ip gave the maximum stimulation o f p38 (Figure 23). Densitometry was
performed on the stimulated bands for graphical representation.
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Effect o f GABA on IL -ip stimulated p38 MAPK
As GABA inhibited the stimulated release o f IL-6 release we wanted to investigate
the mechanism o f GABA inhibiting the stimulated release o f IL-6. From our previous
results we know that p38 MAPK is activated in the mechanism. We postulated that
GABA might be acting through the inhibition of p38 MAPK. We pre-treated our cells
with GABA (lO-lOOOpM) concentrations for 1 h, followed by 15 min incubation with ILip. Protein was extracted from incubated cells and analyzed with Western blotting
technique. Our results suggested that GABA at 100 and 1000 pM completely blocked the
p38 MAPK (Figure 24).

Effect o f SRIF on IL -ip stimulated p38 MAPK
As SRIF inhibited the stimulated release o f IL-6 release we wanted to investigate the
mechanism o f SRIF inhibiting the stimulated release of IL-6. From our previous results
we know that p38 MAPK is activated in the mechanism. We postulated that SRIF might
be acting through the inhibition of p38 MAPK. We pre-treated our cells with SRIF (25100 nM) concentrations for 1 h, followed by 15 min incubation with IL-lp. Protein was
extracted from incubated cells and analyzed with Western blotting teehnique. Our results
suggested that SRIF enhanced the activation o f p38 MAPK (Figure 25).
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CHAPTER 4

DISCUSSION
Alzheimer’s disease is a neurodegenerative disorder. Extensive research is on going
but unfortunately, the cause o f mechanism o f AD is yet unclear. Approximately
2.5million o f cases o f AD are registered alone in United States. Elevated levels of
cytokines are seen in AD. Cytokines at normal levels are required for the cell to carry out
normal function. But elevated and chronic levels o f cytokines lead to neurodegeneration
and disorders like AD. Increased levels o f IL-1 and IL-6 in the senile plaques of AD are
considered as important factors in the progression o f AD.
Amyloid deposits associated with plaques are observed in AD. For the deposition of
amyloid the precursor protein, amyloid precursor protein p (APP) is required as it the
precursor for the formation o f amyloid protein. IL-1 and IL-6 increases APP deposition
and thus play a rolein progression o f AD. In patients with AD IL-1 P and IL-6 enhance
formation o f APP which increases the formation o f plaques which finally leads to AD
(Nagele, 2004). We are interested in investigating the mechanism o f IL -lp stimulation of
IL-6 pathway. Cellular responses such as cell differentiation, apoptosis, and
neurodegeneration must be defined and have important pharmacological significance for
AD treatment.
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Activated IL -lp forms a complex with the IL-1 receptor agonist and interleukin-1
accessory protein which is called eomplexl. Complex 1 leads to the formation of
complex 2 which is composed o f transforming growth factor p activated kinase-1 (TAKl)
and interleukin-1 receptor associate kinase 1 (IRAKI) and Toll like receptor accessory
protein 6 (TRAF6). TRAF6 also plays an role in the activation o f NFkB which further
activates AP-1, a transcription factor. Complex II thus formed activates the MAPK
signaling cascades which includes activation of MAPK kinase kinase which activates the
MAPK kinase and finally activates MAPK. Activated MAPK thus activates its
transcription factors and finally leads to the cell response (Figure 26).
We investigated the pathway o f IL-1 P stimulated IL-6 release in C6 glioma cells
because the activation of these inflammatory cytokines leads to the progression of AD.
As discussed, IL -ip stimulates IL-6 by activating the MAPK signaling cascade; which
plays an important role in the stimulation of IL-6. We therefore want to investigate the
role of p38, JNK , and ERK.
We used the SP600125 inhibitor o f JNK , PD98059 inhibitor o f ERK (Figure 7), and
the SB203580 inhibitor o f p38 ( Figure 6). Previous studies indicated that SP600125 had
no effect on the release o f the IL-6. Therefore we suggest that JNK might not have an
important role in the pathway. Our current results indicated that SB203580 inhibited IL-6
release while PD98059 has no effect on the release of IL-6. As JNK and ERK do not
have a significant effect, we therefore examined p38 activation. We suggest that, p38 is
activated while the other two MAPK are not involved. We proposed that IL-6 is
stimulated by activating p38 and if we can inhibit the activation o f p38 and thereby
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inhibit the release o f IL-6, this will be a great pharmacological significance in the
progression o f AD.
Our next focus is the role of inhibitory neurotransmitter GABA on p38 and IL-6.
GABA is the major inhibitory neurotransmitter in the brain and is present in 40% of all
neurons. It produces an hyperpolarizing inhibitory effects on neurons. By our results
GABA inhibited the release of the IL-6. From the previous results we suggested the
involvement of p38 M APK in the stimulated mechanism o f IL-6. We wanted to
investigate the relationship between p38 and GABA. If GABA can inhibit the activation
p38 then it would be a great progression in the understanding o f IL-1 P signaling events.
We performed western analysis to investigate the involvement o f GABA in p38
activation. Our results suggested that GABA inhibited the activation of p38 dose
dependently and at lOOOpM it completely knocked out the p38. Here we concluded that
GABA acts through inhibiting p38. However, a 100 pM o f GABA completely inhibited
the activation of p38 while it showed only some effect on IL-6 inhibition and this we
suggested that for inhibition of IL-6 which takes place out side the cell may need higher
concentration of GABA. As GABA inhibited both IL-6 and p38 we want to know more
about the mechanism o f action o f GABA and investigated the GABA receptor subclass.
Our next research goal involves the characterization o f GABA subclass receptor.
GABA is composed o f two receptors G A B A a and GABAg. GABA acts through binding
one o f its receptors or both of them. G A BA a acts through the ion channel receptor
(Semyanov 2004; Lambert 2004). It is similar to the acetylcholine receptor. G A BA a
increases the influx o f CF ion channels there by causes hyperpolarization and induces a
hyperpolarization inhibition.
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G A B A b acts through G-protein coupled receptor. It creates an efflux of

channels

from the cell and thereby creates hyperpolarization and inhibition (Bettler 2003). We
treated our cells with muscimol which is a G A BA a receptor agonist and baclofen which
is a G A B A b receptor agonist. Our results suggested that the G A B A b receptor inhibited
the release o f IL-1 P stimulated IL-6 from C6 glioma cells. G A B A a has a moderate effect
and thus we stated G A B A a might not be involved in the mechanism. We hereby
correlated that GABA inhibits p38 by binding through GABAg receptor and suggest that
GABA acts through its metabotropic receptor.
From previous results, SRIF inhibits IL -ip stimulated release o f IL-6 from C6 glioma
cells. We want to know whether SRIF inhibits p38. But, SRIF did not inhibit p38 and we
hereby suggest that SRIF may act through other MAPK (i.e. ERK). We suggest that SRIF
may act through ERK by crosstalk with other MAPK or through other transcription
factors. One o f the possible transcription factors may be nuclear factor - kappa B (NFk
B). NFkB plays an important role in the inflammatory response o f the cell (Azzolina,
2003). It is a heterodimer and helps in the activation o f IL-6. Activation of IKK (IkB
kinase) leads to the degradation of IkB which leads to the activation o f NFkB. This
mechanism is stimulated by the complex which includes the MAPKKK and TRAF6.
Thus activated NFkB leads to the activation o f the transcription factor AP-1. There may
be a possible role of SRIF in the inhibition of IL-6 through NFkB. The role o f NFkB will
be one o f our future studies. Their maybe a possible role for GABA acting through the
NFkB and GABA may act through both mechanisms.
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Our results are consistent with those observed in neuronal cell lines. LPS increases
IL -ip stimulated IL-6 levels from neuronal eells (Li, 2003). Our future studies also
include the role o f the transcription factors like AP-1 and Elk-2 in the pathway. In the
pathway we propose that MAPK leads to the activation o f transcription factors which
finally leads to the cellular responses like growth differentiation, apoptosis and
inflammation. These inflammatory cytokines also cause apoptosis in the neuronal cell
lines in a 24hr incubation time period.
From the Figure 27 we gave a possible mechanism o f GABA inhibition o f IL-6 and
p38. When GABA binds with GABAg besides creating hyperpolarization it inhibits
cAMP there by inhibits release o f IL-6 and activation o f p38. Though hyperpolarization
creates a difference in the electrochemical gradient and inhibits the transfer of message of
message from one neuron to other, inhibition o f cAMP may provide the reason for the
effective GABAg inhibition o f IL-6 release and the difference in the mechanism of action
between GABA a and GABAg.
Our results elarify the mechanism of IL-1 P stimulated IL-6 release. We can also
suggest that is pathway is common to Parkinson’s disease and we see elevated levels of
TNF-a, IL-ip, and IL-6 in Parkinson’s disease. We suggests that p38MAPK plays an
important role in the IE -1P stimulated release o f IL-6 from C6 glioma cells. JNK and
ERK might not be involved in the mechanism. We suggest that IL -lp stimulates the
activation o f p38 MAPK through the upstream MAPKKK and results in the stimulation
of IL-6 release. SB203580 inhibits IL-6 release by inhibiting p38 kinase. GABA also
inhibits the stimulated release o f IL-6. This is achieved by inhibiting p38 acting through,
the GABAg subclass receptor. We proposed a signaling pathway from our results (Figure
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28). IL -lp binds to the IL-1 receptor 1 and activates ERK, and p38 kinase which activates
IL-6 leading to responses like growth differentiation, apoptosis, and inflammation.
GABA, SB203580, and SRIF inhibit the IL -ip stimulated IL-6 release. GABA and
SB203580 achieves via inhibition o f p38 while SRIF may act through ERK kinase.
However, though PD98059 inhibits ERK kinase had no effect on IL-6. Our results are
significant as the mechanism o f IL -1P stimulated release o f IL-6 in C6 glioma cells is
now more clearly described. Treatment for the AD might involve manipulation of
GABAergic neurons in the brain.
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APPENDIX I
FIGURES
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Figure 1: Amino acid sequence of precursor protein for the cytokine IL-1 p. It is a 30.75
kDa molecular weight protein. The region highlighted is the IL-1 domain and it
corresponds from 117 to 269 amino acids. Precursor protein is cleaved by the pro teases at
the highlighted region and the active form o f IL -lp is formed. IL -ip is a 17.3kDa protein.
It is expressed in macrophage, lung and skin.
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Figure 2: Amino acid sequence o f precursor protein for the cytokine IL-6. It is 212 amino
aeid protein with molecular weight of 23.74 KDa. The region highlighted represents the
IL-6 domain from 28-212 amino acids. Precursor protein is cleaved by the protease at the
highlighted region shown by arrow and the active form o f IL-6 is released. The sequence
underlined represents the single peptide (SP) motif from 1-28 amino acids. IL-6 is
expressed in the macrophages, brain, placenta, kidney, and skeletal muscles.
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Figure 3: Schematic representation o f MAP kinase pathway. Any o f the three MAPK
upstream targets are activated by stimulus such as, growth factors, stress, inflammatory
cytokines, or mitogens. MAPKKK thus activated activates MAPKK. MAPKK in turn
activates MAPK which finally lads to the biological response such as growth
differentiation, inflammation, or apoptosis. ERK 1/2 is activated by M EK l/2, three
isoforms o f p38 MAPK are activated by MKK3/6, and SAPK/JNK 1/2/3 is activated by
MKK4/7. (adapted from www.cellsignal.com)
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Figure 4: Chemical structure of GABA. GABA inhibits the IL-1|3 stimulated release of
IL-6 by acting through p38 MAPK. GABA acts by binding to one o f its receptor either to
GABA a or to GABA b receptor. Our results suggested that it acts through GABA b
receptor.
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Figure 5: Chemical structure GABA a agonist museimol. Its chemical name is 5aminomethyl-3-hydroxy-isoxazole.
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Figure 6: Chemical structure o f GABA b agonist baclofen. Its chemical name is P(aminomethyl)-4-chlorobenzenepropanoic
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Figure 7: SB203580 is a p38 MAPK inhibitor. Its chemical name is Pyridine, 4-[5-(4fluorophenyl)-2-[4-(methylsulfmyl)phenyi]-lH-imidazoi-yi]. It inhibits the upstream
activator of p38 MAPK (i.e. MKK3) and MAPKAPK 2 and thus inactivates the p38.
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Figure 8: PD98059 is a ERK MAPK inhibitor. Its chemical name is 2'-Amino-3'methoxyflavone. It inhibits the ERK 1/2 kinase and thus inhibits its downstream targets.
Our results suggested that it has no effect on IL-1 (3 stimulated release o f lL-6.
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Plate C6 cells in a 96 well plate; 100,000 cells/well and a volume Of 200pL and
incubate

i
i
i

Wash the cells 2X with SF-RPMI; Add drugs and incubate

C PayX )
Transfer the media in to a new 96 well plate and label.

C 3 a y 4^
Take a 96 well plate and according to the number o f samples set up for duplicates of
experiment, concentrated and dilute.
Add 180pL o f SF-RPMI to concentrated wells and 150pL in dilute wells.
Add 20pL o f sample to concentrated wells and mix them 15X.
Discard 50pL media from concentrated wells.
Add 50pL o f media from concentrated wells to diluted wells mix then 15X.
Discard lOOpL media from diluted wells.
Add lOOpL o f 7TD1 cells 40,000cells/wells to get a total volume o f 200pL/well and
incubate for 3-4 days.
1

Add 20pL o f MTT to each well and incubate for 3-4 hr s.
Discard 150pL o f media.
Add 150pL o f acidified isopropanol.
Cover the plate with an aluminum foil and store the plates over night in dark.
1

Cp l y 8 ^
Read the Plates and graph it.
Figure 9: Flow chart for the 7TD1 Bioassay.
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Step XPrepare working reagent in the ration o f 25:24:1 with solution A, Solution B, Solution
C.
Working reagent can be stored at Room temperature.
i

Prepare Series o f standard solutions using serial dilution technique with the stock
solution o f 2ng/ML using PBS as a vehicle for dilution.
Prepare 7 standard solution and one blank which is just PBS.

'Step
Add 150pL o f working reagent to the well in a 96 well plate. Now add 150pL of
samples and standards.

Step 4^
Mix the plate on a~plite shaker for 30 sec.

i
<dstep%)
Incubate the plate in the incubator for 2-3 hr s.

i
(^ t e p 6%)
Read the plate at 595 nm plot the graph and by interpolation from standard graph
protein amount in the samples will be calculated.

Figure 10: Flow chart for the Micro BCA protein assay. Protocol is according to the
manufactures protocol.
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y = 0.1077Ln(x) + 0.0436
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Figure 11: Standard curve o f IL-6 is obtained from the known concentrations o f the IL-6
and logarithmic curve was plotted between optical density (OD) and IL-6 concentration
(pg/well). 7TD1 Bioassay was performed and equation was obtained from the graph.
Equation is used for calculating the concentration o f IL-6 in samples.
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Figure 12: Standard curve of IL-6 is obtained from the known concentrations of the IL-6
and linear curve was plotted between optical density (OD) and IL-6 concentration
(pg/well). 7TD1 Bioassay was performed and equation was obtained from the graph.
Equation is used for calculating the concentration o f IL-6 in samples.jksghjksdhgjks
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Figure 13: Effect o f cell number on IL -lp stimulated release o f IL-6. Cultured C6 cells
(nxl0‘^ cells/well) were plated in a 96 well plate. Cells were treated with and with out ILlp. Treated cells are thus incubated for 24hrs and samples are collected for IL-6 release
studies. Release o f IL-6 is measured by using 7TD1 bioassay. Samples are done in
quadruplicates and the error value is calculated using SEM.
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Figure 14: Time course o f IL -ip stimulated release of IL-6. Cultured C6 cells (100,000
cells/well) were plated in a 96 well plate. Cells were treated with and with out IL-lp and
incubated for different time intervals. Samples are collected at different time intervals for
IL-6 release studies. Basal release was not detectable at any time point. Release of IL-6 is
measured by using 7TD1 bioassay. Samples are done in quadruplicates and the error
value is calculated using SEM.
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Figure 15: Dose response o f IL -ip stimulated release of IL-6. Cultured C6 cells (100,000
cells/well) were plated in a 96 well plate. Cells were treated with and with out IL -ip at
different concentrations o f IL -ip. Treated cells are thus incubated for 24hrs and samples
are collected for IL-6 release studies. Release o f IL-6 is measured by using 7TD1
bioassay. Samples are done in quadruplieates and the error value is calculated using
SEM.

42

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

1000

800

600

ô)
2

400

CD

200

-

0

-

0.0

0.2

0.6

0 .4

0.8

1.0

1.2

1.4

OD

Figure 16; ELISA standard curve. Cultured C6 cells (100,000 cell/well) are plated in an
ELISA 96-well plate. Different concentrations o f IL-6 are placed in the cell and
incubated for 24hrs. ELISA standard curve was plotted between OD and 11-6
concentration (pg/Well). Different standards are prepared using serial dilution technique.
Stock solution o f standard is provided by the manufacturer.
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Figure 17: Dose response of IL -ip stimulated release o f IL-6 using ELISA. Cultured C6
cells (100,000 cells/well) were plated in ELISA 96-well plate. Cells were treated with
different concentrations o f IL -ip and IL-6 release is measured after incubating for
24hrs. Samples are done in duplicates and the error value is calculated using SEM.
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Figure 18: Effect o f SB203580 and PD98059 on IL -lp stimulated release o f IL-6.
Cultured C6 cells (100,000 cells/well) were plated in a 96 well plate. Cells were treated
with and with out IL -lp at different concentrations o f IL-lp. Cells treated with inhibitors
are pretreated with inhibitors for one hr and then treated with IL-ip. Treated cells are thus
incubated for 24hrs and samples are collected for IL-6 release studies. Release of IL-6 is
measured by using 7TD1 bioassay. Samples are done in quadruplieates and the error
value is calculated using SEM.
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Figure 19: Effeet o f G ABA on IL -ip stimulated release o f IL-6. Cultured C6 cells
(100,000 cells/well) were plated in a 96 well plate. Cells were treated with and with out
IL -lp at different concentrations o f IL-ip. Cells treated with inhibitors are pretreated
with inhibitors for one hr and then treated with IL-ip. Treated eells are thus incubated for
24hrs and samples are collected for IL-6 release studies. Release of IL-6 is measured by
using 7TD1 bioassay. Samples are done in quadruplicates and the error value is
calculated using SEM.
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Figure 20: Effect o f muscimol (G A B A a receptor agonist) on IL -ip stimulated release of
IL-6. Cultured C6 cells (100,000 cells/well) were plated in a 96 well plate. Cells were
treated with and with out IL -ip at different concentrations o f IL -ip. Cells treated with
receptor agonist are pretreated with inhibitors for one hr and then treated with IL-1 p.
Treated cells are thus incubated for 24hrs and samples are collected for IL-6 release
studies. Release o f IL-6 is measured by using 7TD1 bioassay. Samples are done in
quadruplicates and the error value is calculated using SEM.
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Figure 21: Effeet o f baclofen (GABA b receptor agonist) on IL -ip stimulated release of
IL-6. Cultured C6 cells (100,000 cells/well) were plated in a 96 well plate. Cells were
treated with and with out IL -ip at different concentrations o f IL-1 p. Cells treated with
receptor agonist are pretreated with inhibitors for one hr and then treated with IL-1 p.
Treated cells are thus incubated for 24hrs and samples are collected for IL-6 release
studies. Release o f IL-6 is measured by using 7TD1 bioassay. Samples are done in
quadruplicates and the error value is calculated using SEM.
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Figure 22: Western analysis was conducted on C6 samples. Cells are treated with IL -ip
(25 ng/mL). Samples are collected at different time intervals and protein is extracted from
the samples. Extracted protein thus analyzed using Western blotting technique.
Membrane is treated with phosphorylated p38 primary antibody (Cell signaling) and Anti
-m ouse secondary antibody (KPL Inc). Bar graph represents the densitometry values and
fold increase compared to control.
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Figure 23: Western analysis was conducted on C6 samples. Cells are treated with
different concentrations of IL -ip. Samples are colleeted at 15 min after the cell treatment
with the drug and protein is extracted from the samples. Extracted protein thus analyzed
using Western blotting technique. Membrane is treated with phosphorylated p38 primary
antibody (Cell signaling) and Anti -m ouse secondary antibody (KPL Inc). Bar graph
represents the densitometry values and fold increase compared to control.
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Figure 24; Western analysis was conducted on C6 samples. Cells are pretreated with
GABA for Ihr and treated with different concentrations o f IL-1 p (25ng/mL). Samples are
collected at 15 min after the cell treatment with the drug and protein is extracted from the
samples. Extracted protein thus analyzed using Western blotting technique. Membrane is
treated with phosphorylated p38 primary antibody (Cell signaling) and Anti -mouse
secondary antibody (KPL Inc). Bar graph represents the densitometry values and fold
increase compared to control.
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Figure 25: Western analysis was eonducted on C6 samples. Cells are pretreated with
SRIF for Ihr and treated with different concentrations o f IL -lp. Samples are collected at
15 min after the cell treatment with the drug and protein is extracted from the samples.
Extracted protein thus analyzed using Western blotting teehnique. Membrane is treated
with phosphorylated p38 primary antibody (Cell signaling) and Anti -mouse secondary
antibody (KPL Inc). Bar graph represents the densitometry values and fold increase
compared to control.

52

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.
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channel
m em brane
GABAH cAMP —► IL-6
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Figure 26: Schematie diagram of GABA signaling pathway. When GABA binds to
GABA a it creates an influx of CF ion whieh causes the hyperpolarization o f the
membrane. When it binds to GABA b receptor it creates hyperpolarization by efflux of
ion. GABA b inhibits cAMP.
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Figure 27: Schematic diagram o f IL -ip stimulation of IL-6. We found GABA, Sb203580
inhibit MAPK-p38 their by inhibiting IL-6. PD98059 though inhibits ERK do not have a
significant effect in inhibiting IL-6 stimulated release.
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Figure 28: Pathway and relation between death o f GABAergic neurons and Alzheimer’s
disease. Death o f GABAergic neurons which is an early effect causes the reduction in
levels of GABA which leads to increase in the IL-6 levels leading to AD. At normal
conditions GABA inhibit the IL -lp stimulated release o f lL-6.
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